Are Global Health Systems Ready for Transformative Therapies?

Abstract

Background: We have seen significant advancement in a range of health technologies, some with transformative or curative potential. Nevertheless, it is often unclear how global health systems recognize or reward innovation. Objectives:To consider what is transformative, challenges for transformative therapies, and downstream health ecosystem effects.Methods: A systematic review of publications in English between 2012 and 2018 was conducted with a focus on value assessment processes and health system effects of a range of breakthrough health technology categories. After screening 9012 records, 222 unique studies were identified. The study also included an analysis of 100 health technology assessments (HTAs) from 5 markets to consider how and in what ways global HTA bodies evaluate transformative therapies. Global sales and technology/procedure utilization data were also evaluated to gain insights into patient access and commercial impact.Results: This article evaluated uncertainties around evidence of efficacy, safety, and duration of effect, as well as underlying study quality and methodological considerations in the target categories. Although many HTA evaluations had similar approaches to assessing parameters such as safety, there were significant differences across technology categories. Technologydriven trends also surfaced where global HTA and payer systems may not yet be prepared to recognize and reward emerging technology impacts, including use of next-generation diagnostic results to guide care, considering novel impacts on therapy sequencing and clinical pathway management, and changes in payment and health delivery models.Conclusions: Some trends stemming from rapid evolution of breakthrough therapies will prompt reconsideration of our conventional value assessment and reward models, because health system measurement and management processes have not fully anticipated their effects.

Emerging Workforce Readiness in Regenerative Healthcare

“…Indeed, acceleration in this field is anticipated with ongoing innovation, including for example the introduction of additive manufacturing technology, digital design and use of artificial intelligence for biofabrication of functional organ structure [27]. As regenerative therapies continue to permeate the future clinical landscape with validated solutions and confirmed utility, global readiness for clinical adoption must be prioritized [28,29]. Yet the portal for next-generation healthcare providers to access adequate training in regenerative care counseling remains narrow.…”

<p>Clozapine As Transformative Treatment In Bipolar Patients</p>

“…The great burden of this disease with highest risk of suicide among psychiatric disorders, common psychiatric and somatic comorbidities, treatment resistance and devastating psychosocial consequences calls for more effective treatments 53. Clozapine with its unique pharmacology and epigenetic and neuroplastic effects can become a transformative treatment similarly to antiviral transformative treatments for AIDS or HCV, cell therapies in oncology or gene therapies54 or ketamine in the treatment of depression. It can significantly reduce the great burden of BP I and may modify the course of the disease.…”

Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges

“…The lack of appetite for complex agreements among policy-makers was also noted by Karlsberg Schaffer et al [5], who concluded that 'there is a mismatch between the enthusiasm in the academic literature for developing new approaches and the scepticism of payers that they can work, or are necessary for the foreseeable future'. Secondly, there has been a growth in the application of financed-based and performance-based agreements to drugs rather than to other types of technologies, which could be a response to the growing number of transformational, but highly expensive new drugs entering the market [6]. Many recent reviews of PBRSAs discuss issues that apply to health technologies in general but draw almost exclusively on drugs for their examples [4,[7][8][9].…”